Onyx Accuses Bayer of a Double-Cross Over a Compound Related to Nexavar
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer pursued a “surreptitious” plan to supplant the cancer drug at the heart of a 15-year-old collaboration, according to a harshly-worded lawsuit.
You may also be interested in...
Nexavar Expansion Plans Suffer Another Blow With Failed Lung Cancer Trial
Failed MISSION trial closes a door for Bayer/Onyx’s Nexavar in non-small cell lung cancer. Meanwhile, follow-on regorafenib, also partnered by Bayer and Onyx, is poised for submission in the U.S. and Europe for metastatic colon cancer.
Nexavar Expansion Plans Suffer Another Blow With Failed Phase III Lung Cancer Trial
Failed MISSION trial closes a door for Bayer/Onyx’s Nexavar in non-small cell lung cancer. Meanwhile, follow-on regorafenib, also partnered by Bayer and Onyx, is poised for submission in the U.S. and Europe for metastatic colon cancer, with ASCO presentations ahead.
Partners Onyx And Bayer Settle Next-Gen Nexavar Lawsuit, Enter New Deal
Onyx dropped its lawsuit against partner Bayer in exchange for an agreement that lets it share the financial rewards of the compound at the heart of the controvers, regorafenib, now in Phase III for oncology indications.